Bioequivalence Study of Klaribact (Clarithromycin) 500 mg, Film Coated Tablet.
Status:
Completed
Trial end date:
2012-12-25
Target enrollment:
Participant gender:
Summary
This is An Open Label, Randomized, Single Dose, Two Way Cross over, Two Period, Two
Treatment, Two Sequence Bioequivalence Study to compare the rate and extent of absorption of
Klaribact FC Tablet (Clarithromycin 500 mg) with Reference Product, Klaricid FC Tablet
(Clarithromycin 500 mg) in healthy adult male subjects under fasting condition.
Phase:
Phase 1
Details
Lead Sponsor:
University of Karachi
Collaborators:
Center for Bioequivalence Studies and Clinical Research Merck Pvt. Ltd, Pakistan